NeVa CLEAR Study Results Presented at ESMINT: Innovative Thrombectomy Device Achieves Notable First-Pass Success and Patient Outcomes
Primary results from the CLEAR Study(1) were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of the international commercialization of the NeVa™ device. - September 21, 2023
Vesalio Announces Initial Use of Its Uniquely Designed and FDA-Approved NeVa VS Device for Neurovascular Vasospasm in the United States
Vesalio announces the successful initial use of its NeVa VS device in the United States for the treatment of post-aneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm. Vasospasm is the most common complication of aSAH and is the main cause of delayed morbidity and mortality. NeVa VS is the... - February 23, 2023
Vesalio Appoints VP of U.S. Sales and Announces Recent Publication on NeVa Showing Impressive First Pass Rates
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology. - November 29, 2022
Vesalio Announces EU MDR Certification
This regulatory achievement confirms the company’s commitment to the EU’s new, rigorous quality standards for its innovative medical devices. - October 13, 2022
Vesalio Announces FDA Approval of the NeVa VS™ to Treat Cerebral Vasospasm After Aneurysmal Rupture
NeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture. Delayed cerebral vasospasm is the leading cause of death and disability in patients who suffer an aneurysm rupture. - September 15, 2022
Vesalio Announces CE Approval for New NeVa NET™, the First Integrated Clot Micro-Filtration Technology for Stroke Thrombectomy Patients
NeVa NET™ micro-filtration technology coupled with NeVa’s Drop Zone™ technology creates a one-of-a-kind stent retriever designed to capture every type of clot and maximize clot retention for fast and effective recanalization of ischemic tissue. - September 01, 2022
Vesalio Announces Oversubscribed Class A Financing
Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health... - May 18, 2022
Vesalio Announces the Completion of Enrollment in Its FDA IDE Clinical Study for Acute Ischemic Stroke
Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke. - May 11, 2022
Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to the Company
As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise. - February 03, 2022
Vesalio Announces Appointment of Mike Kujak as Its New Independent Board Chairman
As an independent board chairman, Mike Kujak brings extensive medical start-up expertise. - January 19, 2022
Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI
Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI. - December 23, 2021
Vesalio Secures Class A Funding
Vesalio Secures Class A Funding - June 02, 2021
Vesalio Initiates FDA IDE Stroke Study
Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVa(TM) thrombectomy technology platform. With twenty participating stroke treatment... - May 11, 2021
Vesalio Attains Key FDA Clinical Study Milestone
Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL(1) clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal... - April 28, 2021
Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval
Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels. The new CE approval expands the NeVa™ neuro-thrombectomy portfolio. Vesalio’s Drop Zone(TM) technology, designed to remove... - January 28, 2021
Vesalio Reports 2,500 Patient Milestone
Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic... - December 07, 2020
Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First Pass Effect Rate Publication
Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First Pass Effect Rate Publication - September 16, 2020
Vesalio Obtains Additional CE Approval for New Products, NeVa Clinical Data Published
Vesalio announces it has obtained its second CE mark approval spanning multiple new NeVa™ neurothrombectomy product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first-to-market features such... - May 22, 2019
Vesalio Secures $5 Million Investment Capital Funding
Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions. “We are very pleased to secure the additional capital... - May 14, 2019
Vesalio Reports Expansion of International Distributor Network and Stroke Congress Exhibition Presence
Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System. Along with the increased market and registration activities, Vesalio is... - April 02, 2019
Vesalio Initiates Full Commercial Launch of NeVa at ESMINT Congress
Vesalio Initiates Full Commercial Launch of NeVa at ESMINT Congress - September 12, 2018
Vesalio Reports Expansion of Commercial Distribution, Additional Published Data on the NeVa™ System for Treating Stroke Patients
Vesalio announces it has executed multiple exclusive distribution agreements in Europe and now has market coverage in 25 countries for the NeVa Neurothrombectomy System. All channel partners have been trained on the unique features of the NeVa platform and technique that is optimized for capturing... - June 18, 2018
Vesalio Reports Positive Results in Early NeVa™ Human Thrombectomy Procedures and Recently Published Pre-Clinical Data
Vesalio announces it has completed European enrollment of the first twenty-five human cases in a post-market registry of the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke. With procedures performed at six centers in four countries to date, early results demonstrate... - March 22, 2018
Vesalio Announces NeVa™ Stroke Treatment Product CE Mark Certification
Vesalio announces the CE Mark certification of its first product line, the proprietary NeVa™ neurothrombectomy platform for the treatment of strokes. Developed by a team of physicians that treat stroke, the NeVa mechanical thrombectomy technology was designed to improve “first... - October 31, 2017